Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Pharmacodynamic Models: Additive and Proportional Drug Effect Model01:09

Pharmacodynamic Models: Additive and Proportional Drug Effect Model

Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses01:25

Determination of Multiple Dosing Parameters: Loading and Maintenance Doses

A loading dose is an essential pharmacological strategy to rapidly achieve the target plasma drug concentration necessary for an immediate therapeutic effect. This approach is especially critical for drugs characterized by slow absorption or extended half-lives, where delaying therapeutic plasma levels could compromise treatment outcomes. By administering a loading dose, clinicians ensure a prompt onset of drug action, even for agents with complex pharmacokinetic profiles.Achieving steady-state...
Dose Response Curve: Conventional Versus Nonmonotonic01:21

Dose Response Curve: Conventional Versus Nonmonotonic

The correlation between a drug's dosage and its impact on a biological system is a cornerstone of pharmacology and toxicology. Conventional dose–response curves, which include graded and quantal relationships, are key to this understanding. Graded dose–response curves depict the spectrum of a biological reaction to different doses within an individual, indicating that as the drug dosage increases, so does the intensity of the response. On the other hand, quantal dose–response relationships...
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hand grip support for rehabilitation and assistance: from patent to TRL5.

IEEE ... International Conference on Rehabilitation Robotics : [proceedings]·2022
Same author

Renal impairment and its impact on clinical outcomes in patients who are critically ill with COVID-19: a multicentre observational study.

Anaesthesia·2021
Same author

Ridge regression and its applications in genetic studies.

PloS one·2021
Same author

Loss functions in restricted parameter spaces and their Bayesian applications.

Journal of applied statistics·2020
Same author

Intensive care medicine in 2050: clinical trials designs.

Intensive care medicine·2018
Same author

A proposal for a new PhD level curriculum on quantitative methods for drug development.

Pharmaceutical statistics·2018

Related Experiment Video

Updated: May 8, 2026

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification (ADCI) and Dose Estimation
10:33

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification (ADCI) and Dose Estimation

Published on: September 4, 2017

A Bayesian adaptive dose selection procedure with an overdispersed count endpoint.

L Pozzi1, H Schmidli, M Gasparini

  • 1Division of Biostatistics, University of California, Berkeley, CA, U.S.A.

Statistics in Medicine
|September 12, 2013
PubMed
Summary
This summary is machine-generated.

This study introduces a two-stage Bayesian adaptive design for Phase IIb trials to identify the lowest effective dose. This adaptive approach optimizes dose selection for Phase III studies, improving upon traditional trial designs.

Keywords:
Bayesian inferenceadaptive designclinical trialprobability of successsemi-parametric models

More Related Videos

A Tactile Automated Passive-Finger Stimulator (TAPS)
19:44

A Tactile Automated Passive-Finger Stimulator (TAPS)

Published on: June 3, 2009

Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow
08:58

Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow

Published on: October 17, 2025

Related Experiment Videos

Last Updated: May 8, 2026

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification (ADCI) and Dose Estimation
10:33

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification (ADCI) and Dose Estimation

Published on: September 4, 2017

A Tactile Automated Passive-Finger Stimulator (TAPS)
19:44

A Tactile Automated Passive-Finger Stimulator (TAPS)

Published on: June 3, 2009

Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow
08:58

Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow

Published on: October 17, 2025

Area of Science:

  • Clinical Trial Design
  • Biostatistics
  • Pharmacology

Background:

  • Traditional clinical trial designs can be inefficient.
  • Adaptive trial designs offer flexibility by modifying trial parameters during the study.
  • Phase IIb studies are crucial for dose selection before Phase III.

Purpose of the Study:

  • To propose a novel two-stage Bayesian adaptive design for Phase IIb clinical trials.
  • To efficiently select the lowest effective dose for subsequent Phase III investigations.
  • To improve upon traditional non-adaptive trial designs in dose-finding studies.

Main Methods:

  • A two-stage Bayesian adaptive design is proposed.
  • The design incorporates interim analyses to modify the trial based on predictive probabilities of success.
  • Patients are randomized to placebo, maximal tolerated dose, and other doses, with adaptive dose selection for the second stage.

Main Results:

  • The proposed adaptive design allows for early stopping for futility or success.
  • It enables the selection of an optimal dose for Phase III based on interim data.
  • Simulations are used to evaluate the operating characteristics and compare performance against non-adaptive designs.

Conclusions:

  • The two-stage Bayesian adaptive design offers an efficient method for dose selection in Phase IIb trials.
  • This adaptive strategy can enhance the probability of successfully identifying the lowest effective dose for Phase III.
  • The proposed design demonstrates potential advantages over traditional, non-adaptive approaches.